IMNM
Immunome Inc.
Healthcare • CIK: 0001472012
Loading...
Market Cap
$928.31M
P/E (TTM)
-4.0x
Rev Growth (TTM)
-4.4%
Net Margin (TTM)
-2301.3%
FCF Yield (TTM)
-20.7%
FCF Margin (TTM)
-1982.0%
Cash Flow Health
Free Cash Flow0/8 positive
TTM$-192M
Q3 '25
$-42M+17%
Q2 '25
$-50M+11%
FCF Margin
TTM-1982.0%
Sector: 0.0%Below Avg
OCF Margin-1911.6%
OCF/NI0.83x
CapEx Coverage-27.2x
FCF Yield-20.7%
FCF Growth (2Y)–
Cash Conversion Cycle
0 days
DSO: 0+DIO: –−DPO: –
Capital Allocation & Returns
Total Shareholder Yield
TTM0.0%
Div Yield0.0%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$-191.8M
Capital Return / FCF0.0%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
-94.0%
Volatile
+0.4% YoY+111.2%
P25MedianP75
25th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
-2419.9%
Asset Turnover
0.03x
8Q: 0.04x
Leverage (1+D/E)
1.00x
D/E: 0.00x
DuPont: -81.0% ≈ -94.0% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
0.93x
8Q:1.38x
-564.9%
Invested Cap Turn
0.04x
8Q:0.05x
-7.2%
CapEx Intensity
2.7%
8Q:2.5%
CapEx/Depreciation
2.94x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $9.7M | $0↓100.0% | $4.0M↑37.2% | $2.9M↑6.9% | $2.7M↓5.9% | $2.9M↑23.1% | $2.4M↑129.7% | $1.0M↓73.1% | $3.8M |
Operating Income | $-234.2M | $-60.1M↓29.4% | $-46.5M↓4.1% | $-44.6M | $0↑100.0% | $-83.0M | $0↑100.0% | $-50.5M↓26.3% | $-40.0M |
Net Income | $-222.7M | $-57.5M↓32.4% | $-43.4M↓4.2% | $-41.6M↑48.1% | $-80.2M↓70.4% | $-47.1M↓30.4% | $-36.1M↑72.1% | $-129.5M↓39.8% | $-92.6M |
Operating Cash Flow | $-185.0M | $-40.5M↑18.0% | $-49.4M↑6.9% | $-53.1M↓26.1% | $-42.1M↓23.1% | $-34.2M↓46.0% | $-23.4M↓109.5% | $-11.2M↑36.0% | $-17.5M |
Free Cash Flow | $-191.8M | $-41.6M↑17.3% | $-50.3M↑11.3% | $-56.7M↓31.3% | $-43.2M↓20.9% | $-35.7M↓38.7% | $-25.7M↓93.0% | $-13.3M↑25.1% | $-17.8M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
-4.0x
Volatile
8Q: -15.5x-1001%
Valuation Lenses
Earnings
-4.0x
vs – sector
Cash Flow
-2.6x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: -94.0%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$928.31M
EV–
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
-158/100
Below Average
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Below Avg
-89.4%
8Q:–
Return on Invested Capital (ROIC)Below Avg
-94.0%
8Q:–
+111.2%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: -2419.9%
Asset Turnover: 0.03x
Earnings Quality
Cash Conversion
0.83x
OCF / Net Income
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin–
Capital Efficiency
Invested Capital Turnover0.04x
Working Capital
Cash Conversion Cycle0 days
Growth Quality & Momentum
Low Quality
Growth Quality Score
46/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
-4.4%
OpInc Growth YoY
27.5%
EPS Growth YoY
63.6%
FCF 3Y CAGR
N/A
Growth Quality Analysis
⚠Sustainability Index: 3.0/10 - Growth sustainability concerns
Margin Quality & Sustainability
Moderate
Profitability Cascade
Gross
—
Operating
-2419.9%
Top 25% in sector
Net
-2301.3%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
+319.3 pts
FCF: -1982.0% | Net: -2301.3%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Fortress
Net Debt / EBITDA
Net Cash
(0.0x)Net Cash: $272.85M
Interest Coverage
–
+Net cash position: $272.85M
Leverage Metrics
Debt-to-Equity
0.00x
Balance sheet risk & solvency analysis